aod 9604 and tirzepatide AOD-9604 AOD-9604 – Portland Peptides (ARL)

Ozempic is only approved for patients with Type-2 diabetes

Average weight loss at week 12 was 8.7%, increasing to 17.3% by week 24, and reaching 24.2% by week 48

In-body composition testing, such as the scale at the Nebraska Medicine Bariatric Center, measures body fat and lean muscle percentages, making decision-making about dosing and calorie recommendations easier

Determine effectiveness and tolerability by evaluating symptoms, and use these as the basis for dosage adjustment for most patients

The infant age at follow-up was similar in the GLP1-RA group (neonates aged 028 days, 8%

Next Steps Building on these results, Aon is continuing to track GLP-1 utilization, pricing and outcomes as new indications, products and financing models emerge